These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34673444)

  • 21. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
    Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
    Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
    Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
    J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chronic myelogenous leukemia.
    Kujak C; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(3):113-20. PubMed ID: 26796903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
    Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
    Parker WT; Ho M; Scott HS; Hughes TP; Branford S
    Blood; 2012 Mar; 119(10):2234-8. PubMed ID: 22210874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
    Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
    Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
    Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
    Kagita S; Uppalapati S; Jiwatani S; Linga VG; Gundeti S; Nagesh N; Digumarti R
    Tumour Biol; 2014 Jul; 35(7):7187-93. PubMed ID: 24763825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.
    Cornelison AM; Welch MA; Koller C; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S111-3. PubMed ID: 22035739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
    Erba HP; Pham DC; Zaiden R; Vu H; Tai S
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
    Soverini S; de Benedittis C; Mancini M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
    Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
    Lange T; Ernst T; Gruber FX; Maier J; Cross M; Müller MC; Niederwieser D; Hochhaus A; Pfirrmann M
    Haematologica; 2013 May; 98(5):714-7. PubMed ID: 23065514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
    Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M; Soverini S; De Benedittis C
    Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.